Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy
Victoria F. Gomerdinger, Cassandra Parada, Andrea Li, Aidan Kindopp, Justin A. Kaskow, Eva Cai, Julia Treese, Ivan Susin Pires, Apoorv Shanker, Gil Covarrubias, Alexander D. Stoneman, Magalie Boucher, Paula Therese Hammond
This paper develops a nanoparticle platform to target TLR3 agonist to antigen-presenting cells, improving cancer immunotherapy safety and efficacy by reducing systemic toxicity and enhancing tumor targeting.
bioRxiv · Jun 25, 2026 · PreprintBioengineering